Autoimmune skin diseases are associated with a higher risk for blood cancers, while blistering diseases show no association in a study.

The approval was based on the TRuE-AD3 trial, which evaluated the safety and efficacy of ruxolitinib in pediatric patients aged 2 to 11 years with atopic dermatitis.

The ‘Gasoline’ artist is an open book when it comes to their health journey. Learn all about the various illnesses and health setbacks that Halsey has managed here.

The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with ...